Elekta reports Gamma Knife data as UBS reiterates Sell on Elekta stock

Published on 10/06/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Phase 2 data covered patients with up to 50 brain metastases. Elekta stock costs EUR 4.76 on October 6, 2026 after EUR 4.72, plus 0.85 percent.

Isometrische 3D-Grafik einer Wertschöpfungskette von Labor bis Patientenbett — Isometrische 3D-Illustration der Wertschöpfungskette veranschaulicht den Weg von Forschung bis Patientenversorgung bei Elekta AB SE0000163628, Illustration mit AI erstellt.

Elekta (ISIN SE0000163628) was trading at EUR 4.76 at Lang & Schwarz on October 6, 2026 at 11:14 a.m. CEST, plus 0.85 percent versus the prior close of EUR 4.72. The company reported new phase 2 Gamma Knife data on September 29, 2026, while UBS reiterated a Sell recommendation with a SEK 41.00 target on September 8, 2026.

Gamma Knife expands clinical evidence

According to Elekta, the study evaluated stereotactic radiosurgery in patients with 5 to 50 brain metastases. Investigators reported favorable memory performance two months after treatment, extending the clinical evidence around focal treatment for patients with a higher number of metastases.

The result adds a concrete product signal to Elekta's portfolio, but it is clinical evidence rather than a new sales forecast. The company said more than 2 million patients are treated each year using Elekta solutions across 130 countries, giving the technology a broad installed-base context.

Margin gains offset weaker revenue

The latest reported period was the first quarter of fiscal year 2026/27, ended July 31, 2026. Elekta's revenue was SEK 3.54 billion, while adjusted EBIT reached SEK 389.6 million, according to Stocksentinel.

The comparison is mixed: reported revenue fell 3.00 percent from SEK 3.65 billion in the first quarter of fiscal year 2025/26, while adjusted EBIT rose 68.00 percent from SEK 235.0 million. Adjusted gross margin increased to 42.60 percent from 37.00 percent, a 5.60 percentage point improvement, showing that cost and mix changes carried more weight than the top line.

UBS highlights execution risks

MarketScreener reported on September 8, 2026 that UBS reiterated its Sell recommendation and set a SEK 41.00 target after the first quarter. UBS cited installation delays in China, competition in the United States and cost inflation, while noting that China represented 13.00 percent of Elekta's sales.

That assessment contrasts with management's fiscal-year 2026/27 outlook for 2.00 percent to 4.00 percent constant-currency sales growth and a 12.50 percent to 13.50 percent adjusted EBIT margin. The next scheduled report is the second-quarter report on November 25, 2026, according to Elekta.

Stock remains a measured signal

Elekta stock's modest 0.85 percent gain on October 6, 2026 leaves the market response below the 1.00 percent threshold that would indicate a decisive daily move. For investors, the central tension is visible in the numbers: adjusted EBIT improved 68.00 percent in the first quarter, but revenue declined 3.00 percent and UBS continues to flag regional and competitive risks.

The stock was trading at EUR 4.76 at Lang & Schwarz on October 6, 2026 at 11:14 a.m. CEST, plus 0.85 percent versus the Lang & Schwarz prior close of EUR 4.72. The further course of trading is shown by the continuously updated real-time quote of Elekta stock.